Parabilis Medicines (PBLS) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$2.12
- Estimate
- -$0.24
- Surprise
- -772.9%
- Revenue (period 2026-06-30)
- $148,000
- Score today
- 4.5/10
Revenue source: xbrl.
How the report landed
Parabilis Medicines (PBLS) reported a wider loss than forecast — diluted EPS of -$2.12 against the -$0.24 estimate (a 772.9% shortfall).
Coverage in the report window
- Parabilis Medicines Q2 EPS $(2.32) Misses $(0.08) Estimate, Sales $148.000K Miss $25.000M Estimate — benzinga, 2026-08-13
Where TrendMatrix's rating stands now
TrendMatrix currently rates PBLS Sell at 4.5/10; no pre/post engine snapshot brackets this report.
0 of the last 1 quarters beat the estimate; this quarter's -772.9% surprise compares with a -772.9% four-quarter average. Next scheduled report: 2026-11-12.
What argues against it
- Target reached (-12.9% upside)
- Quality below floor (3.0 < 4.0)
- Negative risk/reward — downside exceeds upside
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $40.75
- Price target
- $46.86
- Stop
- $37.90
- Upside to target
- +15.0%
Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.
PBLS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $4.95B
- P/E (fwd)
- -18.3
- 52-week range
- $24.51–$41.49
- Off 52-week high
- 1.8%
- RSI (14)
- 68
- Volume vs avg
- 1.10×
- Score today
- 4.5/10